{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:19:06Z","timestamp":1758820746453,"version":"3.40.5"},"reference-count":7,"publisher":"Codon Publications","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.aller.2019.12.005","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:49:01Z","timestamp":1585828141000},"page":"792-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Severe atopic dermatitis: Dupilumab is not just safer, but more efficient"],"prefix":"10.15586","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-4068","authenticated-orcid":false,"given":"Mara","family":"Giavina-Bianchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Vicente","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Giavina-Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","reference":[{"issue":"5","key":"10.1016\/j.aller.2019.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol."},{"issue":"14","key":"10.1016\/j.aller.2019.12.005_bib0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.aller.2019.12.005_bib0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"10.1016\/j.aller.2019.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.aller.2019.12.005_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"10.1016\/j.aller.2019.12.005_bib0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A Clinician\u2019s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D."},{"issue":"7","key":"10.1016\/j.aller.2019.12.005_bib0035","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with Dupilumab","volume":"155","author":"Zhu","year":"2019","journal-title":"JAMA Dermatol."}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620300288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054620300288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T22:52:41Z","timestamp":1609455161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301054620300288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0301054620300288"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2019.12.005","relation":{},"ISSN":["0301-0546"],"issn-type":[{"type":"print","value":"0301-0546"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe atopic dermatitis: Dupilumab is not just safer, but more efficient","name":"articletitle","label":"Article Title"},{"value":"Allergologia et Immunopathologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aller.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEICAP. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}